Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Rifapentine for the treatment of pulmonary tuberculosis.

Munsiff SS, Kambili C, Ahuja SD.

Clin Infect Dis. 2006 Dec 1;43(11):1468-75. Review.

2.

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.

Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA.

Int J Tuberc Lung Dis. 2002 Jan;6(1):3-10.

PMID:
11931398
3.
4.

Rifapentine.

Jarvis B, Lamb HM.

Drugs. 1998 Oct;56(4):607-16; discussion 617. Review. Erratum in: Drugs 1999 Apr;57(4):506.

PMID:
9806107
5.

Rifapentine: its role in the treatment of tuberculosis.

Temple ME, Nahata MC.

Ann Pharmacother. 1999 Nov;33(11):1203-10. Review.

PMID:
10573321
6.
7.

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase.

Tam CM, Chan SL, Kam KM, Sim E, Staples D, Sole KM, Al-Ghusein H, Mitchison DA.

Int J Tuberc Lung Dis. 2000 Mar;4(3):262-7.

PMID:
10751074
8.

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2005 Dec 1;172(11):1457-62.

9.

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL.

PLoS Med. 2007 Dec;4(12):e344.

10.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium..

J Infect Dis. 2012 Oct 1;206(7):1030-40.

11.

[A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis].

Zhu LZ, Fu Y, Chu NH, Ye ZZ, Xiao HP, Wang W, Yuan SL, Zhang X, Luo YA, Ma LP.

Zhonghua Jie He He Hu Xi Za Zhi. 2006 Aug;29(8):520-3. Chinese.

PMID:
17074263
12.

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.

Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang YC, Conwell DS, Mosher A, Samuels M, Vernon A; Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia..

Am J Respir Crit Care Med. 2002 Jun 1;165(11):1526-30.

PMID:
12045127
13.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team..

N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210.

14.

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.

Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, Morris JS, Mitchison DA.

Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1726-33.

PMID:
9620898
15.

Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review.

Gao XF, Li J, Yang ZW, Li YP.

Int J Tuberc Lung Dis. 2009 Jul;13(7):810-9. Review.

PMID:
19555529
16.

Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Veziris N, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V.

Antimicrob Agents Chemother. 2005 Oct;49(10):4015-9.

17.

Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.

Zvada SP, Denti P, Geldenhuys H, Meredith S, van As D, Hatherill M, Hanekom W, Wiesner L, Simonsson US, Jindani A, Harrison T, McIlleron HM.

Antimicrob Agents Chemother. 2012 Aug;56(8):4471-3. doi: 10.1128/AAC.00404-12.

18.

[A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous].

He GJ.

Zhonghua Jie He He Hu Xi Za Zhi. 1993 Feb;16(2):73-6, 122. Chinese.

PMID:
8251027
19.

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.

Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6.

20.

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium..

Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210.

PMID:
25489785
Items per page

Supplemental Content

Support Center